Literature DB >> 11578496

Is there an association between long-term tamoxifen treatment and the development of carcinosarcoma (malignant mixed Müllerian tumor) of the uterus?

M.J. Evans1, N.E.I. Langlois, H.C. Kitchener, I.D. Miller.   

Abstract

A cluster of five patients with endometrial carcinosarcoma (malignant mixed Müllerian tumor) occurred at our center during 1993; four of these had been prescribed long-term tamoxifen for breast carcinoma. Searching the archives for the 9-year period 1983-1992 revealed two further cases of uterine carcinosarcoma occurring in patients prescribed tamoxifen, from a total of 16 cases of this tumor. Five of the six patients diagnosed with carcinosarcoma who had been taking tamoxifen had been maintained on the drug for at least 6 years, while the other had a 3-year history of tamoxifen therapy. From these data we raise the question of an association between long-term tamoxifen treatment and development of endometrial carcinosarcoma, following the dramatic increase in the prescribing of this drug after 1984.

Entities:  

Year:  1995        PMID: 11578496     DOI: 10.1046/j.1525-1438.1995.05040310.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  7 in total

1.  Gynaecological effects of tamoxifen.

Authors:  S M Ismail
Journal:  J Clin Pathol       Date:  1999-02       Impact factor: 3.411

Review 2.  My approach to the interpretation of endometrial biopsies and curettings.

Authors:  W G McCluggage
Journal:  J Clin Pathol       Date:  2006-08       Impact factor: 3.411

Review 3.  Tamoxifen in breast cancer ipse dixit in uterine malignant mixed Müllerian tumor and sarcoma-A report of 8 cases and review of the literature.

Authors:  Ana Luisa Cardoso Vasconcelos; Beatriz Nunes; Catarina Duarte; Vera Mendonça; Joana Ribeiro; Marília Jorge; Isabel Monteiro Grillo
Journal:  Rep Pract Oncol Radiother       Date:  2013-08-12

Review 4.  Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas?

Authors:  W G McCluggage
Journal:  J Clin Pathol       Date:  2002-05       Impact factor: 3.411

5.  Tissue microarray analysis of hormonal signaling pathways in uterine carcinosarcoma.

Authors:  Gloria S Huang; Rebecca C Arend; Maomi Li; Marc J Gunter; Lydia G Chiu; Susan Band Horwitz; Gary L Goldberg
Journal:  Am J Obstet Gynecol       Date:  2009-02-06       Impact factor: 8.661

6.  URI1 amplification in uterine carcinosarcoma associates with chemo-resistance and poor prognosis.

Authors:  Yu Wang; Michael J Garabedian; Susan K Logan
Journal:  Am J Cancer Res       Date:  2015-06-15       Impact factor: 6.166

Review 7.  Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives.

Authors:  Salvatore Giovanni Vitale; Antonio Simone Laganà; Stella Capriglione; Roberto Angioli; Valentina Lucia La Rosa; Salvatore Lopez; Gaetano Valenti; Fabrizio Sapia; Giuseppe Sarpietro; Salvatore Butticè; Carmelo Tuscano; Daniele Fanale; Alessandro Tropea; Diego Rossetti
Journal:  Int J Mol Sci       Date:  2017-05-20       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.